Celsion Corp

NASDAQ:CLSN   4:00PM EDT
1.39
+0.31 (+28.69%)
StockTwits Share  Twitter Share  Facebook Share

Search For a Symbol

Market Cap (Intraday)29.73M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats...
Estimates Current Quarter
Revenue$0.13 Million
Adjusted EPS-$0.28
See more estimates...
10-Day MA$1.37
50-Day MA$1.63
200-Day MA$1.91
See more pivots...

Celsion CORP Stock, NASDAQ:CLSN

997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE, NJ 08648
United States of America
Phone: (609) 896-9100
Number of Employees: 19

Description

Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It has a development, product supply, and commercialization agreement with Yakult Honsha Co. Ltd. for ThermoDox; and a commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. for the production of ThermoDox in mainland China, Hong Kong, and Macau. The company also has a collaboration with the Children's Research Institute to conduct a clinical study of ThermoDox, a heat activated liposomal encapsulation of doxorubicin in combination with magnetic resonance-guided high intensity focused ultrasound to treat relapsed or refractory solid tumors in children and young adults. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.